Not Signed In - Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly Prolongs Time To Progression In Previously Treated Multiple Myeloma Patients
Tue, 12 Dec 2006 08:00 AM EST
... Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and VELCADE(R) (bortezomib), the market leader in relapsed or refractory multiple myeloma (MM), report that the combination of medications provides a nearly three-month improvement in time to disease [click link for full article] ...
Related Topics
- Myeloma, Multiple
- Multiple Myeloma
- Myeloma
- Doxorubicin Liposomal Injection
- Data Analysis
- Thalidomide
- Multiple myeloma cancer
- Multiple Myeloma/Other Plasma Cell Neoplasms
- Plasma Cell Neoplasm/Multiple Myeloma
- Multiple Myeloma/Plasma Cell Neoplasm
- Bortezomib
- Multiple Chemical Sensitivity
- Combination Vaccines
- Twins, Triplets, Multiple Births
- Vaccinations For HIV/AIDs Patients
- What Your Female Patients Want to Know About Bladder Control
- more...
- Multiple System Atrophy
- Smoking Cessation and Continued Risk in Cancer Patients
- Combination Diet
email this page
print this page
bookmark this page
feedback on this page
